Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.

Grace M ChoongSavannah LiddellRoberto A Leon FerreCiara C O'SullivanKathryn J RuddyTufia C HaddadTimothy J HobdayPrema P PeethambaramMinetta C LiuMatthew P GoetzKarthik V Giridhar

Published in: Breast cancer research and treatment (2022)

Following progression on a CDK 4/6i, mPFS was short, with similar PFS times comparing chemotherapy and ET, with slightly longer PFS for targeted strategies (PI3K/mTOR). These results highlight a major need to better understand the mechanisms of CDK4/6i resistance and identify new therapeutic strategies for these patients.

Keyphrases

cell cycle
end stage renal disease
newly diagnosed
chronic kidney disease
small cell lung cancer
squamous cell carcinoma
cell proliferation
peritoneal dialysis
patient reported outcomes